Types of Autoimmune Disease: Which Ones Are Being Studied With Stem Cell Therapy?

What This Article Covers

An autoimmune disease develops when the immune system mistakenly attacks the body's own healthy tissue instead of confining its response to foreign invaders. More than 80 recognized autoimmune diseases exist, and they are typically grouped by how broadly the immune attack spreads: organ-specific diseases target a single tissue (the thyroid in Graves' disease, pancreatic beta cells in type 1 diabetes, the skin in vitiligo), while systemic diseases involve autoantigens present throughout the body and can affect joints, skin, kidneys, and organs simultaneously (lupus, rheumatoid arthritis, scleroderma). Because cell-based therapies work by resetting or modulating immune function rather than targeting one organ, researchers see autoimmune disease broadly as a promising category for stem cell and cell-based approaches — but "promising" does not mean "proven," and how far along the science is varies enormously by disease category. This overview maps that landscape at a bird's-eye level; readers wanting depth on any single condition should see this site's dedicated articles.

Rheumatologic (Joint and Connective Tissue) Autoimmune Disease

This category — rheumatoid arthritis, lupus, scleroderma, Sjögren's syndrome, ankylosing spondylitis — has the most cell-therapy activity of any autoimmune category, but at two very different stages of maturity:

• Mesenchymal stem cell (MSC) infusions for rheumatoid arthritis remain early-stage. Multiple clinical studies and reviews describe MSC therapy (often umbilical-cord-derived) as showing encouraging safety and symptom signals, but the evidence base is still built on small trials, and MSC therapy for RA is not an approved treatment (Stem Cell Research & Therapy, 2025; Rheumatology & Autoimmunity, 2026).
• CAR-T cell therapy for lupus and related systemic autoimmune disease is the more genuinely exciting frontier right now. Small early trials — including an allogeneic CD19-targeted CAR-T study published in Cell Research (2025) and separate cohorts described by the Lupus Foundation of America — have reported durable drug-free remission in some patients with severe, treatment-refractory lupus, in some cases lasting up to three years. Data presented at ACR Convergence 2025 on newer dual-target constructs (targeting both CD19 and BCMA) were also described by the American College of Rheumatology as showing "encouraging safety, efficacy, and cellular kinetics." These results are genuinely notable because they involve patients who had exhausted standard therapies — but every study to date involves only a handful to a few dozen patients, trials remain restricted to refractory disease, and serious risks like cytokine release syndrome and neurotoxicity are real considerations still being characterized in this population.

Gastrointestinal Autoimmune Disease (IBD: Crohn's Disease and Ulcerative Colitis)

Cell therapy in IBD splits into two distinct tracks. The most clinically mature is a localized application: darvadstrocel (brand name Alofisel), an allogeneic MSC product injected directly into complex perianal fistula tracts in Crohn's disease, was approved for this specific indication in the European Union based on the original ADMIRE-CD trial. It's worth noting honestly, though, that a larger confirmatory phase 3 trial (ADMIRE-CD II) found darvadstrocel was not significantly better than placebo, a result Takeda first announced in 2023 and that was published in full in Gastroenterology in 2026 — and Takeda withdrew Alofisel from the EU market in December 2024 as a result. Separately, systemic MSC infusion for luminal Crohn's disease or ulcerative colitis (treating the whole-body inflammatory disease rather than one fistula) remains investigational, with only small phase 1/2 studies and systematic reviews describing safety and preliminary efficacy signals, not established treatment.

Neurologic Autoimmune Disease (Multiple Sclerosis)

This is the one category where a stem-cell-based approach has moved furthest along the evidence spectrum. Autologous hematopoietic stem cell transplantation (AHSCT) — which uses the patient's own blood stem cells to rebuild the immune system after chemotherapy wipes out the disease-driving immune cells — now has joint recommendations from ECTRIMS and EBMT (published in Nature Reviews Neurology, 2024) supporting its use in relapsing-remitting MS that has failed high-efficacy disease-modifying therapy, particularly in aggressive disease. Recent cohort data show progression-free survival in the 80–100% range and treatment-related mortality below 0.3% with modern protocols, a marked improvement from historical rates. That said, AHSCT is not a general first-line MS treatment, is based mostly on observational rather than large randomized trial data (only two RCTs exist), carries meaningfully higher upfront risk than standard MS drugs, and shows little benefit in progressive MS forms — so it occupies a genuine but narrow, specialist-directed niche rather than a mainstream option.

Endocrine and Dermatologic Autoimmune Disease

Type 1 diabetes (endocrine) and vitiligo or psoriasis (dermatologic) represent organ-specific autoimmune disease where cell-based research is active but generally earlier-stage than the rheumatologic or neurologic categories — focused on protecting or replacing the specific damaged cell population (islet cells, melanocytes, keratinocyte-immune interactions) rather than the broad immune-resetting approaches used in MS or lupus. This site's dedicated articles on each condition cover trial specifics in more depth.

Bottom Line

Autoimmune disease is not one problem but a spectrum, from single-organ conditions to whole-body systemic disease, and stem cell and cell-based research reflects that spectrum unevenly. AHSCT for aggressive relapsing MS is the closest thing to an established, specialist-endorsed cell-based option in this category, backed by international transplant-society recommendations. CAR-T for severe, refractory lupus is the most exciting emerging development, with real (if very small-scale) remission data. MSC therapy for rheumatoid arthritis and systemic IBD remains earlier-stage investigational science, and even the one approved MSC product in this space (for Crohn's fistulas) has an evidence record that includes a failed confirmatory trial and subsequent market withdrawal. Across every category, the through-line is the same: promising signals exist, but most cell-based therapy for autoimmune disease remains investigational, restricted to clinical trials or narrow specialist settings, and not a substitute for established, guideline-based treatment.